Protara Historical Financial Ratios
| TARA Stock | USD 2.94 0.34 13.08% |
Protara Therapeutics is promptly reporting on over 97 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 5.73, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.13 will help investors to properly organize and evaluate Protara Therapeutics financial condition quickly.
Protara |
About Protara Financial Ratios Analysis
Protara TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Protara Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Protara financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Protara Therapeutics history.
Protara Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Protara Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Protara Therapeutics sales, a figure that is much harder to manipulate than other Protara Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from Protara Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Protara Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.At present, Protara Therapeutics' Days Payables Outstanding is projected to increase significantly based on the last few years of reporting. The current year's Income Quality is expected to grow to 1.13, whereas PTB Ratio is forecasted to decline to 0.30.
| 2020 | 2021 | 2022 | 2023 (projected) | PB Ratio | 0.88 | 0.47 | 0.3 | 0.31 | Capex To Depreciation | 4.51 | 5.09 | 0.48 | 0.13 |
Protara Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Protara Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protara Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 11.37 | 0.17 | 0.88 | 0.47 | 0.3 | 0.31 | |
| Book Value Per Share | 99.2 | 27.54 | 14.41 | 9.07 | 6.03 | 5.73 | |
| Free Cash Flow Yield | (14.82) | (0.14) | (0.46) | (0.88) | (1.77) | (1.85) | |
| Operating Cash Flow Per Share | (242.81) | (3.24) | (3.07) | (2.35) | (3.31) | (3.48) | |
| Capex To Depreciation | 1.03 | 0.0573 | 4.51 | 5.09 | 0.48 | 0.13 | |
| Pb Ratio | 11.37 | 0.17 | 0.88 | 0.47 | 0.3 | 0.31 | |
| Free Cash Flow Per Share | (243.06) | (3.36) | (3.12) | (2.36) | (3.32) | (3.48) | |
| Roic | (2.34) | (0.17) | (0.29) | (0.64) | (0.63) | (0.66) | |
| Net Income Per Share | (228.6) | (4.63) | (4.2) | (5.76) | (3.57) | (3.75) | |
| Payables Turnover | 0.0223 | 0.21 | 1.22 | 0.16 | 0.14 | 0.13 | |
| Cash Per Share | 95.92 | 23.31 | 8.12 | 7.49 | 5.79 | 5.5 | |
| Pocfratio | (0.0675) | (7.48) | (2.2) | (1.14) | (0.57) | (0.6) | |
| Capex To Operating Cash Flow | (0.001023) | (0.0378) | (0.0173) | (0.004536) | (0.001198) | (0.001258) | |
| Pfcf Ratio | (0.0675) | (7.21) | (2.16) | (1.14) | (0.57) | (0.59) | |
| Days Payables Outstanding | 16.3K | 1.7K | 298.38 | 2.3K | 2.6K | 3.9K | |
| Income Quality | 1.04 | 0.69 | 0.73 | 0.4 | 0.93 | 1.13 | |
| Roe | (2.3) | (0.17) | (0.29) | (0.63) | (0.59) | (0.62) | |
| Ev To Operating Cash Flow | 0.33 | (0.33) | (1.37) | (0.47) | 0.34 | 0.36 | |
| Pe Ratio | (0.0717) | (5.23) | (1.61) | (0.47) | (0.53) | (0.55) | |
| Return On Tangible Assets | (2.11) | (0.19) | (0.33) | (0.57) | (0.51) | (0.54) | |
| Ev To Free Cash Flow | 0.33 | (0.31) | (1.35) | (0.47) | 0.34 | 0.36 | |
| Earnings Yield | (13.94) | (0.19) | (0.62) | (2.15) | (1.9) | (1.99) | |
| Net Debt To E B I T D A | 0.94 | 0.79 | 4.96 | 0.62 | 0.27 | 0.75 | |
| Current Ratio | 11.96 | 58.13 | 21.66 | 15.01 | 11.17 | 21.0 | |
| Tangible Book Value Per Share | 99.2 | 23.46 | 11.79 | 9.07 | 6.03 | 5.73 | |
| Graham Number | 714.29 | 53.58 | 36.89 | 34.27 | 22.0 | 20.9 | |
| Shareholders Equity Per Share | 99.2 | 27.54 | 14.41 | 9.07 | 6.03 | 5.73 | |
| Capex Per Share | 0.25 | 0.12 | 0.0531 | 0.0107 | 0.003971 | 0.003773 | |
| Graham Net Net | 86.88 | 22.77 | 7.22 | 6.58 | 4.87 | 4.62 | |
| Enterprise Value Over E B I T D A | 0.66 | (0.23) | (1.03) | (0.19) | 0.3 | 0.31 | |
| Price Earnings Ratio | (0.0717) | (5.23) | (1.61) | (0.47) | (0.53) | (0.55) | |
| Price Book Value Ratio | 11.37 | 0.17 | 0.88 | 0.47 | 0.3 | 0.31 | |
| Price Earnings To Growth Ratio | (3.3E-5) | 0.0533 | 0.17 | (0.0125) | 0.0139 | 0.0146 | |
| Days Of Payables Outstanding | 16.3K | 1.7K | 298.38 | 2.3K | 2.6K | 3.9K | |
| Price To Operating Cash Flows Ratio | (0.0675) | (7.48) | (2.2) | (1.14) | (0.57) | (0.6) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.